home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

58.51 -0.56 (-0.95%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

4 Incomparable Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market ↗

May 18, 2024

Plain-as-day bargains can still be found, even with the innovation-fueled Nasdaq Composite powering to a fresh all-time high.

Via The Motley Fool

Topics Stocks

Walmart To Rally Over 17%? Here Are 10 Top Analyst Forecasts For Friday ↗

May 17, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 15, 2024

Via Benzinga

Analyst Ratings For Biomarin Pharmaceutical ↗

May 14, 2024

Via Benzinga

(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest ↗

May 09, 2024

Via Benzinga

Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings) ↗

April 25, 2024

Via Benzinga

Looking Into Biomarin Pharmaceutical's Recent Short Interest ↗

April 03, 2024

Via Benzinga

The Latest Analyst Ratings For Biomarin Pharmaceutical ↗

February 23, 2024

Via Benzinga

The 3 Best Biotech Stocks to Buy in May 2024 ↗

May 09, 2024

If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May.

Via InvestorPlace

Citi Just Cut Its Price Target on These 3 Stocks ↗

May 03, 2024

Reviewing analyst downgrades may help safeguard investment portfolios amid market uncertainty and Citi price target cuts.

Via InvestorPlace

For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering. ↗

April 30, 2024

For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.

Via Chartmill

4 Dominant Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market ↗

April 27, 2024

Opportunistic investors can still find bargains, even with the Nasdaq Composite up 49% since the start of 2023.

Via The Motley Fool

Topics Stocks

3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition ↗

April 25, 2024

Many fortunes have been made with a fortuitous investment in a biotech stock at the right time. That time might be now.

Via InvestorPlace

Recap: Biomarin Pharmaceutical Q4 Earnings ↗

February 22, 2024

Via Benzinga

Decoding 8 Analyst Evaluations For Biomarin Pharmaceutical ↗

January 30, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical ↗

December 21, 2023

Via Benzinga

Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

April 25, 2024

Via Benzinga

BMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Misses Revenue for Q1 2024 ↗

April 24, 2024

BMRN stock results show that Biomarin Pharmaceutical beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 24, 2024

Via Benzinga

Don't overlook NASDAQ:BMRN—a stock with solid growth prospects and a reasonable valuation. ↗

April 08, 2024

Investors seeking growth at a reasonable cost should explore BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN).

Via Chartmill

While growth is established for NASDAQ:BMRN, the stock's valuation remains reasonable. ↗

March 18, 2024

Despite its growth, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) remains within the realm of affordability.

Via Chartmill

4 Extraordinary Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market ↗

March 16, 2024

Although the Nasdaq Composite is galloping to record highs, amazing deals among growth stocks can still be uncovered.

Via The Motley Fool

Topics Stocks

Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN. ↗

February 26, 2024

For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.

Via Chartmill

7 Biotech Stocks Fighting America’s Deadliest Diseases ↗

February 08, 2024

Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.

Via InvestorPlace

3 No-Brainer Stocks to Buy With $200 Right Now ↗

February 07, 2024

A reasonably small amount of money can go a long way when it's put to work in innovative, industry-leading businesses.

Via The Motley Fool

4 Marvelous Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

January 20, 2024

A greater than 7% decline in the Nasdaq Composite from its record high signals that opportunistic investors can still find bargains.

Via The Motley Fool

Topics Stocks

If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names ↗

January 10, 2024

Biotech is one of the areas of interest in the market today, adding a biotech stock could be huge play this month.

Via InvestorPlace

4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

December 02, 2023

An 11% decline in the Nasdaq Composite over the past two years is an open invitation for opportunistic growth investors to go shopping.

Via The Motley Fool

Topics Stocks

Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures ↗

November 09, 2023

Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments.

Via InvestorPlace

3 Promising Biotech Stocks Flying Under the Radar ↗

November 08, 2023

Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com